These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 10365287

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
    Bounameaux H, Ehringer H, Gast A, Hulting J, Rasche H, Rapold HJ, Reber G, Tschopp TB.
    Thromb Haemost; 1999 Apr; 81(4):498-501. PubMed ID: 10235427
    [Abstract] [Full Text] [Related]

  • 24. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.
    Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM.
    Circulation; 1995 Apr 01; 91(7):1929-35. PubMed ID: 7895349
    [Abstract] [Full Text] [Related]

  • 25. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
    Direct Thrombin Inhibitor Trialists' Collaborative Group.
    Lancet; 2002 Jan 26; 359(9303):294-302. PubMed ID: 11830196
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase.
    Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR.
    Thromb Haemost; 1996 Sep 26; 76(3):339-43. PubMed ID: 8883267
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C.
    Linder R, Blombäck M, Egberg N, Grip L.
    Thromb Res; 1999 Jul 15; 95(2):117-25. PubMed ID: 10418800
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.
    Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR.
    J Am Coll Cardiol; 1994 Nov 15; 24(6):1445-52. PubMed ID: 7930274
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
    Averkov OV, Slavina NN, Gratsianskiĭ NA.
    Kardiologiia; 2003 Nov 15; 43(10):50-9. PubMed ID: 14593356
    [Abstract] [Full Text] [Related]

  • 36. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
    Christersson C, Oldgren J, Bylock A, Wallentin L, Siegbahn A.
    J Thromb Haemost; 2005 Oct 15; 3(10):2245-53. PubMed ID: 16194202
    [Abstract] [Full Text] [Related]

  • 37. Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog.
    Ignasiak DP, McClanahan TB, Bousley RE, Juneau PL, Gallagher KP.
    J Thromb Thrombolysis; 1998 Nov 15; 6(3):199-206. PubMed ID: 10751802
    [Abstract] [Full Text] [Related]

  • 38. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
    Lancet; 1999 Feb 06; 353(9151):429-38. PubMed ID: 9989712
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
    Elg M, Gustafsson D, Deinum J.
    Thromb Haemost; 1997 Oct 06; 78(4):1286-92. PubMed ID: 9364999
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.